Evolution of therapies in deep vein thrombosis management

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6 SUPPL. 2, 1999, Pages

  Ten Cate, J W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Deep vein thrombosis; Evolution; History; Low molecular weight heparin; Outpatient therapy; Prophylaxis; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DESULFATOHIRUDIN; DEXTRAN; ENOXAPARIN; FIBRINOLYTIC AGENT; GLUCOSE POLYMER; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; COMPRESSION THERAPY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG HYPERSENSITIVITY; HUMAN; HYPERVOLEMIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

DISEASE MANAGEMENT; EVOLUTION; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; VENOUS THROMBOSIS;

EID: 0032849693     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Kakkar VV. Prevention and management of venous thrombosis. Br Med Bull 1994; 50: 871-903.
2. National Institutes of Health. Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. J Am Med Ass 1986; 256: 744-749.
3. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled study. Lancet 1960; i: 1309-1312.
4. Eskeland G, Solheim K, Skjorten F. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fracture; a controlled clinical trial. Acta Chir Scand 1966; 131: 16-29.
5. Rippl E, Scheffler P, Gross J, Schieffer H. New trends in diagnosis and therapy of phlebothrombosis. Therapiewoche 1996; 46: 1303-1306.
6. Brandjes DPM, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the inital treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
7. International Multicentre Trial. Prevention of postoperative pulmonary embolism by low doses of heparin. Lancet 1972; ii: 45-51.
8. Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, Candardjis G. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983; 309: 954-958.
9. Nicolaides AN, Bergqvist D, Hull R, Ackchurin RS, Allegra C, Arcelus J, et al. Consensus statement: prevention of venous thromboembolism. Int Angiol 1997; 16: 3-38.
10. Johnsson SR, Bygdeman S, Eliasson R. Effect of dextran on postoperative thrombosis. Acta Chir Scand 1968; 387 (suppl): 80-82.
11. Allan A, William JT, Bolton JP, Le Quensne LP. The use of graduated compression stockings in the prevention of post-operative deep vein thrombosis. Br J Surg 1988; 70: 172-174.
12. Gallus A, Ramon K, Darby T. Venous thrombosis after hip replacement; the influence of preventive intermittent calf compression and of surgical techniques. Br J Surg 1983; 70: 17-19.
13. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643.
14. Schafer AI. Low-molecular-weight heparin for venous thromboembolism. Hosp Pract 1997; Jan 15: 99-106.
15. Gibaldi M, Wittkowsky AK. Contemporary use of and future roles for heparin in antithrombotic therapy. J Clin Pharmacol 1995; 35: 1031-1045.
16. Young E, Wells P, Holloway S, Weitz J, Hirsch J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-304.
17. Bergqvist D. Low molecular weight heparins. J Intern Med 1996; 240: 63-72.
18. Pineo GF, Hull RD. Prevention and treatment of venous thromboembolism. Drugs 1996; 52: 71-92.
19. Hunt D. Low-molecular-weight heparins in clinical practice. South Med J 1998; 91: 2-10.
20. Hirsh J. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemost 1996; 26 (suppl 4): 189-198.
21. Bounameaux H, Goldhaber SZ. Uses of low-molecular-weight heparin. Blood Rev 1995; 9: 213-219.
22. Wheatley T, Veitch PS. Editorial II. Recent advances in prophylaxis against deep vein thrombosis. Br J Anaesth 1997; 78: 118-120.
23. Leyvraz PF, Bachmann F, Hock J, Buller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303: 543-548.
24. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes D, Vandenbroucke J, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
25. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-920.
26. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.
27. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-607.
28. Colwell CWJ, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, et al. Use of enoxaparin, a low molecular weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994; 76-A: 3-14.
29. Clagett GP, Anderson FA, Heit J, Lavine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (suppl): 312S-334S.
30. Bergqvist D, Matsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T, et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in the prevention of thrombosis after elective general surgery. Br J Surg 1988; 75: 888-891.
31. Dahl S, Andreassen G, Muller C, Mathisen P, Nyhus S, Aspelin T, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis and pulmonary embolism 35 days after hip replacement surgery. Thromb Haemost 1995; 73: 1904 (Abstract).
32. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228.
33. Kakkar VV, Cohen AT, Edmonsen RA, Phillips MJ, Cooper DJ, Das SK, et al., on behalf of the Thromboprophylaxis Collaborative Group. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265.